BTC$62,291.00+3.20%
ETH$1,626.48+5.83%
USDT$0.9995+0.00%
BNB$591.85+3.54%
USDC$0.9996+0.00%
XRP$1.14+5.57%
SOL$64.60+5.18%
TRX$0.3286+3.15%
FIGR_HELOC$1.03+0.46%
HYPE$58.79+0.64%
DOGE$0.0843+5.16%
USDS$0.9997+0.01%
LEO$9.55-0.31%
RAIN$0.0134+4.90%
XLM$0.2048+5.05%
ZEC$398.76+9.00%
BTC$62,291.00+3.20%
ETH$1,626.48+5.83%
USDT$0.9995+0.00%
BNB$591.85+3.54%
USDC$0.9996+0.00%
XRP$1.14+5.57%
SOL$64.60+5.18%
TRX$0.3286+3.15%
FIGR_HELOC$1.03+0.46%
HYPE$58.79+0.64%
DOGE$0.0843+5.16%
USDS$0.9997+0.01%
LEO$9.55-0.31%
RAIN$0.0134+4.90%
XLM$0.2048+5.05%
ZEC$398.76+9.00%
Rockwell Automation, Inc. reported a challenging start to fiscal 2025 with an 8.4% decline in sales, primarily attributed to lower organic sales and currency translation impacts.
TSMC faces revenue challenges due to a $161 million impact from a January earthquake, but remains optimistic about its long-term growth strategy.
T-Mobile's collaboration with Starlink introduces a space-based mobile network to eliminate dead zones in the U.S.
Honeywell plans to split into three publicly traded companies to enhance shareholder value, driven by Elliott Management's influence.
Tesla is experiencing a significant decline in European sales, particularly in Germany, due to backlash against CEO Elon Musk.
Apple Inc. faces challenges from new U.S. tariffs and a potential Chinese antitrust investigation.
Electronic Arts reported a slight earnings miss for Q3 FY2025 but boosted investor confidence with a $1 billion stock repurchase plan.
AMD's stock dropped over 10% after Citi downgraded its rating due to concerns about slowing AI growth.
Uber is set to announce its fourth-quarter earnings with expectations of an 18.3% year-on-year revenue growth.
PayPal exceeded fourth-quarter financial expectations but faced a share decline due to concerns over slowing card processing growth.
Ontario retaliates against U.S. tariffs by removing American alcohol products from its shelves.
Bitcoin's value drops below $100,000 amid geopolitical tensions, tariff impacts, and trading fluctuations.
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.